site stats

Parithera

WebParithera enables accurate treatment decision guidance & monitoring from one simple blood draw An alternative to tissue biopsy is to study cells which detach from the solid … WebIn this video Parithera shares a bit about who they are, how being part of Geneus helped their company and a birthday wish to Campus Biotech Innovation Park ...

Early diagnosis of resistant cancer ETH Zurich

Web8 Dec 2024 · See Parithera funding rounds, investors, investments, exits and more. Evaluate their financials based on Parithera's post-money valuation and revenue. Parithera Stock … Web22 Mar 2024 · Parithera aims at developing Circulating Tumor Cells (CTC) monitoring and liquid biopsies to better understand diagnostics and treatments follow-up for cancer … buyers signature of authorization meaning https://p4pclothingdc.com

Volumina Medical, Parithera and PeriVision win the Biopôle …

Web26 Nov 2024 · Parithera receives an Innogrant © 2024 EPFL The EPFL Tech Launchpad is pleased to announce they have granted an award of CHF100,000 to Parithera – an EPFL-startup which improves the efficacy … WebAiming to bring the first reliable diagnostics to detect cancer treatment resistance early, Parithera has created an innovative integrated platform that identifies circulating tumour cells (CTCs) that have detached from a solid tumour and are travelling in the bloodstream. WebParithera ExTrace enables clinicians to monitor treatment response and choose the best therapy based on single cell RNA (scRNA) sequencing data. Parithera’s innovative … buyers sl66ac

Parithera raises CHF 100 000 from FIT - BioAlps

Category:Mélanie Op – Metropolregion Lausanne Berufsprofil

Tags:Parithera

Parithera

Parithera - Tech Stack, Apps, Patents & Trademarks - CrunchBase

Web2 Mar 2024 · Aiming to bring the first reliable diagnostics to detect cancer treatment resistance early, Parithera has created an innovative integrated platform that identifies circulating tumor cells (CTCs) that have detached from … WebParithera is the provider of a minimally invasive, inexpensive, and highly actionable cancer diagnosis platform to guide treatment decisions of clinicians. The company was founded …

Parithera

Did you know?

Web11 Apr 2024 · Cancer Therapy Evaluation Program study 9557 (ClinicalTrials.gov identifier NCT02097225) is a phase 1 study that was designed to assess the safety and efficacy of the small-molecule HSP90 inhibitor, AT13387, in combination with dabrafenib and trametinib in BRAF V600E/K –mutant solid tumors. Web28 Mar 2024 · Aiming to bring the first reliable diagnostics to detect cancer treatment resistance early, Parithera has created an innovative integrated platform that identifies circulating tumour cells (CTCs) that have detached from a solid tumour and are travelling in the bloodstream. Currently, over 90% of patient deaths are due to treatment resistance ...

WebParithera aims to revolutionize cancer diagnosis. To help them bring their technology forward Biopôle chose to support the company with the Biopôle Start-up ... Web21 Jan 2024 · Parithera, led by Dr. Antoine Herzog (CEO) and Dr. Weida Chen (CTO), both originally from ETH Zurich and now located at EPFL, provides a minimally invasive, inexpensive and highly actionable cancer diagnosis platform to …

WebGlassdoor gives you an inside look at what it's like to work at Parithera, including salaries, reviews, office photos, and more. This is the Parithera company profile. All content is posted anonymously by employees working at Parithera. WebWhat is it really like to work at Parithera? What do employees say about pay and career opportunities? Discover anonymous reviews now!

WebParithera . Connect to CRM . Save . Summary Financials People Technology Signals & News Similar Companies. Highlights. Active Tech Count 17. About. Parithera is actively using 17 technologies for its website, according to BuiltWith. These include Viewport Meta, IPhone / Mobile Compatible, and SPF.

WebParithera’s goal is to save lives by providing a minimally invasive diagnostic which analyses cancer treatment resistance and allows clinicians to adjust treatment regimen. Activity or … buyers side boxWebParithera is a company that operates in the Internet industry. It employs 21-50 people and has $1M-$5M of revenue. The company is headquartered in Switzerland. Read More. Headquarters: Switzerland. Website: www.parithera.com. Revenue: <$5 Million. Parithera's Social Media. Is this data correct? SIC Code 80,72. buyers significatoWeb12 Aug 2024 · Born two years ago as a project, Parithera was incorporated in June 2024. As the founders explain to Startupticker.ch, there is a large unmet need to precision diagnostics in oncology. By combining technologies from ETHZ and EPFL, Parithera can fill that gap. The startup will focus on 2 markets: 1) Biopharma development by supporting ... buyers smc35aWebParithera is the provider of a minimally invasive, inexpensive, and highly actionable cancer diagnosis platform to guide treatment decisions of clinicians. The company was founded in 2024 and is based in Epalinges, Switzerland. Headquarters Location Startlab, Bât. Alanine Route de la Corniche 5 Epalinges, 1066, Switzerland Suggest an edit cell security camera systemsWebParithera is funded by École Polytechnique Fédérale de Lausanne. Funding Rounds. Edit Funding Rounds Section. Number of Funding Rounds 1. Total Funding Amount CHF100K. Parithera has raised a total of CHF100K in funding over 1 round. This was a Grant round raised on Nov 26, 2024. buyers sl66agWebparithera. The Vision. Our Mission. The ExTrace. The Process. Partnerships. Careers. Contact. Scroll for more. Inquire. Please rotate your device in portrait mode for the best … cell security cameraWebParithera Aug. 2024–Jan. 20246 Monate Epalinges, Vaud, Suisse The goal of this startup is to design a microfluidic device that allows a good … buyers silver coins